FDA Approves ZANVASTRO for Alexander Disease; Ionis Secures Priority Review Voucher

summarizeSummary

Ionis Pharmaceuticals received FDA approval for ZANVASTRO (zilganersen) to treat Alexander disease in pediatric and adult patients, along with a Priority Review Voucher. The drug is the first disease-modifying therapy for this ultra-rare condition and will launch in the U.S. in the coming weeks.

check_boxKey Events · Product Development and Regulatory · IONS

• FDA Approves ZANVASTRO for Alexander Disease

  ZANVASTRO (zilganersen) is the first and only disease-modifying treatment for Alexander disease in pediatric and adult patients, an ultra-rare, progressive, and often fatal neurological disorder.

• Priority Review Voucher Granted

  The FDA granted Ionis a Rare Pediatric Disease Priority Review Voucher, which can accelerate a future regulatory review or be sold to another company.

• Pivotal Study Met Primary Endpoint

  ZANVASTRO 50 mg demonstrated statistically significant stabilization of gait speed vs control at Week 61 (least square mean difference 33.3%, p=0.041).

• U.S. Launch Imminent

  ZANVASTRO will be available in the U.S. in the coming weeks, marking Ionis' first independent launch from its neurology pipeline and second independent launch this year.

auto_awesomeAnalysis · IONS · Life Sciences

The FDA approved ZANVASTRO (zilganersen) as the first and only disease-modifying treatment for Alexander disease, an ultra-rare and often fatal neurological disorder. The approval also grants Ionis a Rare Pediatric Disease Priority Review Voucher, a valuable asset that can accelerate future regulatory reviews or be sold. ZANVASTRO marks Ionis' first independent launch from its neurology pipeline and second independent launch this year, with U.S. availability expected in the coming weeks. The pivotal study met its primary endpoint with a 33.3% least square mean difference in gait speed stabilization (p=0.041), supporting the approval.